- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02010944
A Study to Compare How Much Solifenacin Succinate and Mirabegron Reach the Blood When Administered Together as Fixed-dose Combination Tablets and With Single Individual Tablets of the Same Medications at Three Dose Levels
An Open-label, Parallel Group, Randomized, Two-sequence, Three-way Crossover Study to Assess the Relative Bioavailability of Solifenacin Succinate and Mirabegron Fixed-dose Combination Tablets Compared to Co-administration of Single Entity Tablets at Three Dose Strengths in Healthy Male and Female Subjects
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
There are three parallel groups each with 24 healthy male and female subjects (with a minimum of 10 subjects per gender). Each group receives one dose strength.
The study utilizes a partial replicate cross-over design with three periods and each subject receives the same strength of either the FDC or SET formulation twice.
Screening takes place within 21 days before admission and subjects are admitted on Day -1. Dosing takes place on Day 1, after an overnight fast of at least 10 hours. Subjects remain fasted until 4 hours post-dose. There is a wash-out period of at least 14 days between each dose administration.
Subjects are discharged on Day 4 and return to the clinical unit on Days 5, 6, 7, 9 and 11 for outpatient assessments.
An End-of-Study Visit (ESV) takes place on Day 11 of Period 3 or within 7-14 days after discontinuation.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Berlin, Germany, 14050
- Parexel
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male subject must agree to not donate semen from the day of first dosing until 3 months after last discharge and practice an effective contraceptive method with female sexual partners to prevent pregnancy.
- Female subject must be of non-child bearing potential, i.e. postmenopausal, surgically sterilized, hysterectomy in medical history, or practicing highly effective non-hormonal birth control.
Exclusion Criteria:
- Female subject who is pregnant, has been pregnant within 6 months before screening or breast-feeding within 3 months before screening.
- Known or suspected hypersensitivity to solifenacin succinate, mirabegron or any components of the formulations used.
- The subject has/had febrile illness or symptomatic, viral, bacterial (including upper respiratory infection), or fungal (non-cutaneous) infection within 1 week prior to admission to the clinical unit.
- Any significant blood loss, donated one unit (450 mL) of blood or more, or received a transfusion of any blood or blood products within 60 days or donated plasma within 7 days prior to clinic admission on Day -1.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: BASIC_SCIENCE
- Allocation: RANDOMIZED
- Interventional Model: CROSSOVER
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: 1: FDC-SET-SET
Fixed Dose Combination followed by two periods of the Single Entity Tablets
|
oral
Other Names:
oral
Other Names:
oral
Other Names:
|
EXPERIMENTAL: 2: SET-FDC-FDC
Single Entity Tablets followed by two periods of Fixed Dose Combination
|
oral
Other Names:
oral
Other Names:
oral
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Pharmacokinetic parameter of solifenacin in plasma as measured by Cmax (Maximum concentration)
Time Frame: Days 1-11
|
Days 1-11
|
Pharmacokinetic parameter of solifenacin in plasma as measured by AUClast (AUC until last sample taken)
Time Frame: Days 1-11
|
Days 1-11
|
Pharmacokinetic parameter of solifenacin in plasma as measured by AUCinf (AUC extrapolated until infinity)
Time Frame: Days 1-11
|
Days 1-11
|
Pharmacokinetic parameter of mirabegron in plasma as measured by Cmax (Maximum concentration)
Time Frame: Days 1-11
|
Days 1-11
|
Pharmacokinetic parameter of mirabegron in plasma as measured by AUClast (AUC until last sample taken)
Time Frame: Days 1-11
|
Days 1-11
|
Pharmacokinetic parameter of mirabegron in plasma as measured by AUCinf (AUC extrapolated until infinity)
Time Frame: Days 1-11
|
Days 1-11
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pharmacokinetic profile of Solifenacin in plasma
Time Frame: Days 1-11
|
AUC0-72h (Area under the plasma concentration-time curve from time zero to 72h), tmax (Time to attain Cmax), tlag (Absorption lag time), t1/2 (Apparent terminal elimination half-life), Vz/F (Apparent volume of distribution), CL/F (Apparent total body plasma clearance)
|
Days 1-11
|
Pharmacokinetic profile of mirabegron in plasma
Time Frame: Days 1-11
|
AUC0-72h (Area under the plasma concentration-time curve from time zero to 72h), tmax (Time to attain Cmax), tlag (Absorption lag time), t1/2 (Apparent terminal elimination half-life), Vz/F (Apparent volume of distribution), CL/F (Apparent total body plasma clearance)
|
Days 1-11
|
Safety and tolerability of solifenacin succinate and mirabegron assessed by adverse events, vital signs, laboratory tests, physical examination and 12-lead electrocardiogram (ECG)
Time Frame: Screening to End of Study Visit (Day 11 Period 3 or within 7 to 14 days after discontinuation)
|
Screening to End of Study Visit (Day 11 Period 3 or within 7 to 14 days after discontinuation)
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Physiological Effects of Drugs
- Adrenergic Agents
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Muscarinic Antagonists
- Cholinergic Antagonists
- Cholinergic Agents
- Urological Agents
- Adrenergic Agonists
- Adrenergic beta-Agonists
- Adrenergic beta-3 Receptor Agonists
- Mirabegron
- Solifenacin Succinate
Other Study ID Numbers
- 178-CL-103
- 2012-002650-23 (EUDRACT_NUMBER)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy Subjects
-
BiogenCompletedHealthy Adult Subjects | Healthy Elderly SubjectsUnited States
-
PfizerCompletedHealthy Adult Subjects and Healthy Elderly SubjectsBelgium
-
Lund UniversityCompletedHealthy Subjects | Diet, HealthySweden
-
PfizerRecruitingHealthy Subjects | Healthy ParticipantsUnited States
-
National Heart, Lung, and Blood Institute (NHLBI)CompletedHealthy | Healthy Subjects | ImmunosuppressionUnited States
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
NeuShen TherapeuticsNot yet recruiting
-
GEN İlaç ve Sağlık Ürünleri A.Ş.Sulfateq B.V.Recruiting
-
Bio-innova Co., LtdNot yet recruiting
-
Bio-innova Co., LtdNot yet recruiting
Clinical Trials on mirabegron
-
The Affiliated Ganzhou Hospital of Nanchang UniversityActive, not recruiting
-
Astellas Pharma IncCompletedHealthy Subjects | Plasma Concentration of MirabegronJapan
-
Thomas Jefferson UniversityAstellas Pharma IncTerminatedAchalasiaUnited States
-
Astellas Pharma IncCompletedHealthy Subjects | Bioavailability | Pharmacokinetics of MirabegronNetherlands
-
Cedars-Sinai Medical CenterRecruitingSyncope | Postural Orthostatic Tachycardia Syndrome | Chronic Orthostatic IntoleranceUnited States
-
Far Eastern Memorial HospitalRecruitingOveractive Bladder SyndromeTaiwan
-
Far Eastern Memorial HospitalRecruitingFemale Patients With Overactive Bladder SyndromeTaiwan
-
Astellas Pharma Europe Ltd.CompletedUrologic Diseases | Urinary Bladder Diseases | Urinary Bladder OveractiveUnited States, Armenia, Australia, Austria, Belgium, Canada, Czechia, Denmark, Finland, France, Georgia, Germany, Greece, Hungary, Ireland, Israel, Italy, Lebanon, Netherlands, Norway, Poland, Portugal, Romania, Russian Federation, Slov... and more
-
Peking Union Medical College HospitalNot yet recruiting
-
Astellas Pharma China, Inc.CompletedPharmacokinetics of Mirabegron | Food Effect | Healthy Chinese SubjectsChina